PMC6635723_01
(A): MRI, nine weeks prior to the therapy, revealing the metastatic mass in the liver with an impending IVC compression (IVC diameter: 18.4 x 8.1 mm), (B): CT scan, Twelve months after last PRRT cycle with significant decompression of the vein (IVC diameter: 30.9 x 19.9 mm)
EXCLI-18-273-g-001.jpg
PMC6635723_01_EXCLI-18-273-g-001.jpg
F1
IVC (Figure 1A(Fig. 1)). In addition, an intense uptake (SUV max: 60.78) was detected on the 68gallium DOTATOC PET/CT, confirming progressive liver metastasis (Figure 2A(Fig. 2)). 
68gallium DOTATOC PET/CT; (A): Seven weeks prior to the therapy, revealing intense tracer uptake in the liver lesion (SUV max: 60.78), (B): Twelve months after last PRRT cycle with significant decreased tracer uptake (SUV max: 8.62)
EXCLI-18-273-g-002.jpg
PMC6635723_01_EXCLI-18-273-g-002.jpg
F2
IVC (Figure 1A(Fig. 1)). In addition, an intense uptake (SUV max: 60.78) was detected on the 68gallium DOTATOC PET/CT, confirming progressive liver metastasis (Figure 2A(Fig. 2)).  PET/CT scans 4, 6 and 12 months after the last PRRT cycle revealed further decreasing tracer uptake in liver segment I (SUV max: 7.82) and a very good palliative therapy outcome, in particular with significant reduction of the tumor mass and decompression of the ICV (30.9 x 19.9 mm vs. 18.4 x 8.1 mm) (Figure 2B(Fig. 2)).